We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Device Measures Hemoglobin More Accurately in Individuals with Darker Skin Pigmentations

By LabMedica International staff writers
Posted on 31 Oct 2022
Image: New tech aims to reduce racial disparities in blood measurements (Photo courtesy of University of Texas at Arlington)
Image: New tech aims to reduce racial disparities in blood measurements (Photo courtesy of University of Texas at Arlington)

Racial disparities in hemoglobin and blood oxygen measurements are an urgent public health issue. The devices presently in use are inaccurate in people with dark skin. Most methods for monitoring hemoglobin require blood samples and expensive equipment. Currently available pulse-oximeters use red-infrared light and are based on technology first designed more than 50 years ago. The available noninvasive spectroscopic methods have a high degree of variability and often are inaccurate in people of color due to differences in skin melanin. There is a significant unmet need for a reliable, noninvasive device to estimate hemoglobin, irrespective of skin color. Now, researchers have demonstrated a new device that measures hemoglobin more accurately in individuals with darker skin pigmentations by using the spectroscopic properties of hemoglobin in the blue-green light spectra.

In a clinical study, a team of researchers at the University of Texas at Arlington (Arlington, TX, USA) along with Shani Biotechnologies LLC (Austin, TX, USA) measured the hemoglobin and oxygen content of 16 healthy volunteers using the newly developed technology. The team compared the results to those obtained using a commercially available pulse-oximeter for accuracy and variability. The findings of the study are encouraging, and the new technology has massive potential to address this clinical unmet need. The researchers intend to develop a wearable device, such as a watch or a monitor, that would read the blood through the skin.

“We have used the green-blue light and have successfully tested the device in preclinical and clinical studies,” said Dr. Vinoop Daggubati of Shani Biotechnologies LLC. “Our group has addressed the issues around shorter wavelength, scattering of light and the impact of skin melanin. The scientific community should open its mind to the concept of green light for these measurements. The Shani device has huge potential to eliminate this racial disparity.”

Related Links:
University of Texas at Arlington 
Shani Biotechnologies 

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Multi-Chamber Washer-Disinfector
WD 390

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM